USF and c-Myc are basic helix-loop-helix transcription factors with similar DNA-binding specificities, but antagonistic effects on cellular transformation. In order to determine how these opposite functions correlate with the transcriptional activities of the two factors on particular downstream targets, we investigated the roles of USF and c-Myc in expression of CDK4, a known direct target of cMyc. Overexpression of either c-Myc or USF2, but not USF1, stimulated the expression of CDK4 promoterdriven reporter genes in the non-tumorigenic mammary epithelial MCF-10A cells. Dominant-negative mutants specific to either Myc or USF family proteins inhibited reporter gene activity as well as endogenous CDK4 expression, demonstrating involvement of both USF and Myc in CDK4 transcriptional control. In contrast, in two different breast cancer cell lines where USF is transcriptionally inactive and c-Myc is overexpressed, CDK4 promoter activity was no longer responsive to either transcription factor. Accordingly, chromatin immunoprecipitation revealed significantly lower levels of both USF and c-Myc bound to the endogenous CDK4 promoter in breast cancer cells than in MCF-10A cells, with a concomitant decrease in associated histone H3 acetylation. These results suggest that a major switch in the transcriptional control of CDK4 occurs during breast carcinogenesis, with likely alteration of cell cycle regulation.
Introduction
Many important biological processes are regulated by transcription factors that belong to the basic helixloop-helix (bHLH) group of proteins. Among these are members of the USF and Myc families, which are implicated in controlling cellular growth and proliferation. Within the Myc family, c-Myc is most notable because of its common involvement in different types of cancers (Dang, 1999) . As a heterodimer with Max, cMyc binds to gene promoters and enhancers at specific E-box elements characterized by a CACGTG core sequence and regulates transcription by RNA polymerase II (Eisenman, 2001) . Expression of c-Myc is repressed in quiescent cells, and induced by various proliferative signals (Persson et al., 1985) . Overexpression of c-Myc promotes cell cycle re-entry in the absence of growth factors (Eilers et al., 1991) , which suggests a causeand-effect relationship between the constitutive expression of c-Myc in tumor cells and abnormal proliferation.
Unlike c-Myc, which requires a dimerization partner to bind DNA, the members of the USF family, USF1 and USF2, form stable homodimers, although US-F1.USF2 heterodimers are the most abundant form of USF in many cell types (Sirito et al., 1994) . All USF proteins share DNA-binding specificity and recognize E boxes that are very similar to the consensus c-Mycbinding site (Bendall and Molloy, 1994; Sirito et al., 1994; Sawadogo, 1988; Szentirmay et al., 2003) . However, the function of USF in cellular proliferation appears quite different from that of c-Myc. In particular, USF can specifically prevent cellular transformation induced by c-Myc overexpression, as detected by in vitro focus formation assay in rat embryonic fibroblasts (Luo and Sawadogo, 1996a) . Ectopic expression of USF in general, and USF2 in particular, inhibits growth in a number of cancer cell lines (Luo and Sawadogo, 1996a) . Finally, the ability of USF to function as a transcriptional activator is impaired or lost in many cancer cell lines, which suggests involvement of USF in tumor suppression Qyang et al., 1999; Szentirmay et al., 2003) .
The mechanisms by which USF antagonizes the stimulatory effect of c-Myc on cellular proliferation is likely to involve activation or repression of particular downstream targets that are responsive to both transcription factors. Among the genes with essential E boxes in their promoters and important for cell cycle progression or cell growth is CDK4, which was identified by serial analysis of gene expression as a direct target of c-Myc (Hermeking et al., 2000) . Understanding the regulation of CDK4 expression and activity is a key point in cancer research since cell cycle regulators are commonly altered in tumors. In a complex with cyclin D, CDK4 controls the progression of cells through the G1 phase of the cell cycle by phosphorylating the retinoblastoma protein (pRb), thereby inactivating the pRb transcription repression function (Matsushime et al., 1992; Harbour et al., 1999) . The enzymatic activity of CDK4 is modulated during the cell cycle by members of the CIP/KIP and INK4 families of CDK inhibitors, which specifically bind to CDK4 (Harper et al., 1993; Polyak et al., 1994; reviewed in Sherr and Roberts, 1999) . Due to the partially redundant function of CDK6, CDK4 knockout mice are viable. However, these animals are smaller in size and infertile, and often develop insulin-deficient diabetes due to a reduction in b-islet pancreatic cells (Rane et al., 1999) . Embryonic fibroblasts from CDK4-null mice proliferate normally, but show delayed S-phase re-entry after quiescence (Rane et al., 1999; Tsutsui et al., 1999) .
There is ample evidence for a role of the CDK4 gene in carcinogenesis. First, CDK4 disruption renders primary mouse cells resistant to oncogenic transformation both in vitro and in vivo (Rodriguez-Puebla et al., 2002; Zou et al., 2002) . Second, overexpression of CDK4, together with activated Ras, is sufficient to induce neoplastic transformation, at least in epidermal cells (Lazarov et al., 2002) . Finally, CDK4 is mutated in a variety of human tumors, including frequent amplification of the chromosomal locus and missense mutations yielding a kinase that no longer interacts with the INK4 inhibitors (reviewed in Ortega et al., 2002) . These CDK4 missense mutations in mice induce tumor development at an early age and in a variety of organs (Sotillo et al., 2001) .
Given the importance of CDK4 in cell cycle regulation and cancer, it is essential to understand how its expression is regulated. The transcriptional regulation of CDK4 expression in normal versus cancer cells has not been thoroughly studied. Yet there is ample evidence for increased expression in cancer, especially breast cancer (Ito et al., 1996; Sasano et al., 1997; An et al., 1999) . Here, we investigated the role of bHLH transcription factors in CDK4 expression in mammary epithelial cells using a combination of overexpression, dominant-negative mutant, and chromatin immunoprecipitation (ChIP) methods. The results of these analyses indicate that CDK4 is jointly controlled by transcription factors USF and c-Myc in the MCF-10A non-tumorigenic breast cell line. In contrast, in two different breast cancer cell lines, CDK4 transcription is independent of both USF and c-Myc and is controlled instead by other, as yet uncharacterized, E-box-binding factors. Considering the central role of CDK4 in cell cycle regulation, this switch in transcriptional control may be a key event in breast carcinogenesis leading to deregulated cellular proliferation.
Results

Binding of USF to multiple E boxes in the CDK4 promoter
The CDK4 promoter contains four highly conserved Ebox elements (Hermeking et al., 2000) . As illustrated in Figure 1a , these E boxes contain the CACGTG core sequence that is characteristic of both Myc-and USFbinding sites, and interaction of c-Myc with these E Figure 1 USF binds to multiple E boxes in the CDK4 promoter. (a) Nucleotide sequence of the CDK4 proximal promoter region showing the location of the four USF-type E boxes relative to the transcription start site (arrow). (b) Recombinant USF1 (rUSF) binding was analysed by DNase I footprinting on a 5 0 -radiolabeled probe spanning nucleotides À292 to þ 4 of the CDK4 promoter. Lane G: G-specific chemical reaction of the same probe. Lanes 1-7: Footprinting reactions with increasing concentrations of rUSF (0-0.4 mg/ml). A schematic representation of the probe with the location of the USF-binding sites is shown at right boxes was previously demonstrated (Hermeking et al., 2000) . All four of the CDK4 E boxes also contain a 5 0 T residue adjacent to the core sequence, a feature known to enhance USF binding (Bendall and Molloy, 1994) . The ability of USF to bind to these E boxes in vitro was examined by DNase I footprinting using a singly endlabeled DNA fragment encompassing nucleotides À292 to þ 4 of the CDK4 promoter and bacterially expressed, recombinant USF (Figure 1b) . On this fragment, USF binding protected the DNA from cleavage at four distinct regions centered on the four E boxes. Each of these USF footprints was about 20 bp and extended 3 0 into a region of enhanced DNase I cleavage, as previously observed for other USF-binding sites (Sawadogo and Roeder, 1985; Szentirmay et al., 2003) . The footprints for a range of USF concentrations in the binding reaction did not suggest preferential USF binding to any of the CDK4 E boxes, since all four footprints appeared at the same USF concentration (Figure 1b) . From this analysis and the previously published data (Hermeking et al., 2000) , we concluded that the CDK4 E boxes were DNA elements capable of binding both c-Myc and USF.
Functional importance of the CDK4 E boxes in nontumorigenic breast epithelial cells
The functional importance of the CDK4 promoter E boxes in human mammary epithelial cells was determined by transient transfection assay using as a model system the non-tumorigenic, spontaneously immortalized MCF-10A cell line. Reporter constructs for this analysis contained the CDK4 promoter region from À214 to À13 with either wild-type (w.t.) (CACGTG) or mutated core sequences (CACCTG) at the various E boxes, as depicted in Figure 2a . Single point mutations in individual E boxes lowered reporter gene activity, but these effects were relatively small (Figure 2b ). Single mutation of the second E box had the strongest effect, reducing promoter activity to 30% that of the w.t.
promoter. Note that this was somewhat different from the results obtained in RAT1 cells, where E boxes 3 and 4 were the most important for CDK4 promoter activity (Hermeking et al., 2000) .
Stronger impairment of CDK4 promoter activation in MCF-10A cells was observed for constructs containing mutations in two or three of the E boxes. Finally, combined mutation of all four E boxes essentially abolished promoter activity, strongly suggesting involvement of E-box-binding proteins in activating the CDK4 promoter in MCF-10A cells (Figure 2b ).
Both USF2 and c-Myc transactivate the CDK4 promoter in MCF-10A cells Involvement of specific transcription factors in the Ebox-dependent expression of the CDK4 promoter in MCF-10A cells was examined by transient cotransfection assay (Figure 3) . First, responsiveness of the promoter to exogenously expressed USF1, USF2, or cMyc was assessed (Figure 3a ). This analysis revealed selectivity in the response of the promoter to different Ebox-binding factors. Reporter gene activity was increased by about 4.5-fold in USF2-overexpressing cells and by about 2.5-fold in c-Myc-overexpressing cells. In contrast, overexpression of USF1 had essentially no effect on CDK4 promoter activity in MCF-10A cells (Figure 3a) .
To confirm the involvement of both USF and Myc family members in CDK4 promoter activation, specific dominant-negative mutants were employed to interfere with binding of the endogenous transcription factors to the CDK4 reporter gene. The A-USF and A-Max constructs were chosen for this analysis because of their specificity and efficiency in inhibiting the DNA-binding activity of proteins of the USF or Myc family, respectively (Krylov et al., 1997; Qyang et al., 1999) . A nearly fivefold decrease in the activity of the CDK4 promoter was observed in the presence of cotransfected A-USF, indicating an essential role of endogenous USF
Figure 2 E-box requirement for the activity of the CDK4 promoter in MCF-10A cells. (a) Schematic representation of the reporter constructs, with w.t. and mutated E boxes depicted as white and black rectangles, respectively. In the mutated E boxes, the central CACGTG sequence of the USF-binding sites was changed to CACCTG. The name of each reporter construct is shown at left. (b) Reporter gene activity was determined by transient transfection assay in MCF-10A cells using cotransfected pRL-SV40 as internal control. Firefly luciferase measurements from three independent experiments were corrected for the activity of the Renilla luciferase internal control, then averaged and normalized to the values calculated for the w.t. CDK4 promoter in activating transcription from the CDK4 E boxes ( Figure 3b ). Cotransfection of A-Max was also inhibitory to CDK4 promoter activity, although to a lesser extent than A-USF, consistent with involvement of endogenous Myc-family proteins in control of CDK4 expression. Taken together with the overexpression results, these dominant-negative mutant results indicated joint regulation of the CDK4 promoter by USF2 and c-Myc, with USF2 playing a prominent role in the case of transiently transfected reporters.
Domains of USF2 required for transactivation of the CDK4 promoter USF1 and USF2 are extremely conserved in the Cterminal bHLH domain and, consequently, exhibit identical dimerization and DNA-binding specificities (Sirito et al., 1994) . Because USF2 but not USF1 stimulated transcription through the CDK4 E boxes in MCF-10A cells, we examined the contribution of USF2 domains to this specific activity. The divergent Nterminal regions of the USF1 and USF2 proteins each contain multiple domains involved in transcriptional activation (Kirschbaum et al., 1992; Luo and Sawadogo, 1996b) . In addition, USF1 and USF2 share a highly conserved domain, the USR, which is both necessary and sufficient for activation of initiator element-containing promoters in HeLa cells (Luo and Sawadogo, 1996b) .
USF2 deletion mutants were cotransfected with the pCDK4-Luc reporter gene in MCF-10A cells (Figure 4 ). The various mutants were expressed at similar levels ( Figure 4c ), but showed different abilities to stimulate or repress CDK4 transcription compared to the contribution of endogenous transcription factors, including endogenous USF (Figure 4b ). Two mutants, USF2DB and USF2DN, were strongly inhibitory, in agreement with their ability to function as dominant-negative mutants. USF2DB lacks the basic region necessary for DNA binding. Thus, specific dimerization of USF2DB with endogenous USF produces DNA-binding-incompetent heterodimers, thereby depleting the pool of endogenous USF proteins capable of activating transcription. USF2DN binds DNA as avidly as w.t. USF proteins, but lacks all N-terminal sequences involved in transcription activation. Thus, binding of USF2DN to E boxes inhibits transcription by preventing access of active transcription factors to the promoter DNA. Strong inhibition by USF2DB and USF2DN indicated that transactivation of CDK4 required both specific DNA binding by USF and interaction with additional transcription factors through one or several USF2 Nterminal domains that are missing in USF2DN ( Figure 4a) .
Several mutants lacking different USF N-terminal sequences were partially active, suggesting that more than one N-terminal USF domain participated in transcriptional activation of the CDK4 promoter. For example, U2DUSR, lacking only the USR, and U2D (7-186), containing no N-terminal domain other than the USR, gave intermediate reporter activities, suggesting that the USR contributed, but was insufficient for full activity. In contrast to mutants with partial activity, a mutant lacking the exon-5-encoded domain, U2DE5, showed CDK4 promoter activation equivalent to w.t. USF2 in MCF-10A cells (Figure 4b ). This last observation provided additional evidence that the mechanisms controlling USF2 activity differ in both a cell typespecific and promoter-specific fashion, given that the exon-5-encoded domain was essential for stimulation of TATA box-containing promoters in HeLa cells (Luo and Sawadogo, 1996b; Qyang et al., 1999) .
Endogenous CDK4 mRNA and protein expression in MCF-10A cells is also jointly controlled by USF and Myc
To extend the results of reporter gene assays to the in vivo situation, it was important to determine whether Western blot analysis indicated a much stronger effect of the USF-and Myc-specific dominant-negative mutants on expression of the endogenous CDK4 protein (Figure 5b) . Quantitation of the immunoblot revealed a 4.9-fold decrease in CDK4 protein for A-USF-transfected cells and a 2.5-fold decrease for A-Max-transfected cells. As a control, cells were transfected with the corresponding empty vector and processed in an identical fashion. There was no change in CDK4 protein expression in the control cells (Figure 5b ). The inhibitory effects of A-USF and A-Max on endogenous CDK4 gene expression in its normal chromosomal context further established the dual control of this gene by USF and c-Myc. Earlier studies demonstrated a frequent loss of USF transcriptional function in breast cancer cell lines. The USF1 and USF2 proteins, although present at similar levels in breast cancer cells as in MCF-10A or in earlypassage human mammary epithelial cells, do not activate transcription of transiently transfected reporter genes in breast cancer cells . Loss of USF function in breast cancer cell lines was also recently documented for one of the direct targets of USF in mammary epithelial cells, the IGF-2 receptor (IGF2R) (Szentirmay et al., 2003) . However, unlike CDK4, IGF2R is a USF-specific target and does not bind cMyc. It was therefore of interest to determine whether cMyc overexpression could compensate for the loss of USF function in activating CDK4 in breast cancer cell lines.
In both MCF-7 and MDA-MB-231 cells, the activity of the CDK4 reporter with mutations in all four CDK4 E boxes (construct m1-4; see Figure 2a ) was considerably weaker than that of the corresponding w.t. reporter, indicating that, as in MCF-10A, CDK4 transcription in breast cancer cells involved E-box-binding transcription factors (Figure 6 ). However, in contrast to the results obtained in MCF-10A, expression of A-USF had no significant effect on w.t. CDK4 promoter activity in these two cancer cell lines. This result indicated that the loss of USF function in breast cancer cells is of a general nature and may affect many if not all of its transcriptional targets. More surprising was the fact that expression of A-Max also failed to inhibit the activity of the CDK4 promoter in MCF-7 or MDA-MB-231 cells (Figure 6 ), suggesting that CDK4 transcription in breast cancer cells was independent of not only USF binding, but also c-Myc binding to the E boxes. Accordingly, overexpression of either USF1, USF2, or c-Myc in MCF-7 or MDA-MB-231 cells failed to stimulate expression of cotransfected CDK4 reporter genes over the level due to endogenous transcription factors (data not shown).
Transcription factor occupancy and chromatin modification at the endogenous CDK4 promoter in normal versus breast cancer cell lines
We used ChIP, combined with quantitation of the immunoprecipitated DNA by real-time PCR, to compare transcription factor occupancies at the cellular CDK4 promoter in the non-tumorigenic MCF-10A cells versus the MCF-7 and MDA-MB-231 cancer cells. Earlier studies showed that loss of USF function in cancer cells did not affect the capacity of the USF proteins to bind DNA in vitro or even in vivo . However, quantitative ChIP analysis revealed that significantly less USF was bound to the CDK4 promoter in the cancer cell lines than in MCF-10A (Figure 7a ). For both USF1 and USF2, the amount of co-precipitated DNA represented between 4 and 5% of the total genomic DNA input for reactions carried out with crosslinked MCF-10A chromatin, while this amount was reduced to about 2 and 0.5% for MCF-7 and MDA-MB-231 chromatin, respectively. In these analyses, the specificity of the USF interaction with the CDK4 E boxes was assessed by measuring the amount of co-precipitating DNA from the CDK4 exon 8 region. This amount was in all cases small (o0.03% of total genomic input; Figure 7) .
Interestingly, c-Myc binding to the CDK4 promoter, as revealed by ChIP assay, was also drastically decreased in the breast cancer cell lines compared to the level observed in MCF-10A (0.05% of genomic input DNA immunoprecipitated, as compared to 0.5% for MCF-10A; Figure 7b ). Given that c-Myc is considerably more abundant in the cancer cell lines than in MCF-10A , the discovery that there was less c-Myc bound to the CDK4 promoter in these cells was unexpected. However, this result was in agreement with the transient transfection data Figure 6 CDK4 promoter activity in breast cancer cell lines is Ebox-dependent, but USF-and Myc-independent. The w.t. CDK4 promoter and quadruple E-box mutant m1-4 luciferase constructs were transfected into MCF-7 (a) or MDA-MB-231 cells (b) to evaluate the role of the CDK4 E boxes in cancer cells (black bars). The pCDK4-Luc reporter was cotransfected with expression vectors encoding A-USF or A-Max to evaluate transcription factor involvement (white bars) (Figure 6 ), which also indicated loss of c-Myc activity at the CDK4 promoter in the cancer cell lines.
In the absence of a compensating mechanism, the decreased binding of both USF and c-Myc to the promoter of the endogenous CDK4 gene in MCF-7 and MDA-MB-231 cells would be expected to yield reduced CDK4 expression in these cancer cell lines as compared to MCF-10A. However, this is clearly not the case. As revealed by Western blot analysis (Figure 8a ), the CDK4 protein is instead overexpressed in the two cancer cell lines. Considering this overexpression, together with the importance of the E boxes for activity of the CDK4 promoter in transiently transfected MCF-7 and MDA-MB-231 cells (Figure 6 ), it is logical to postulate that other positively acting transcription factors occupy the CDK4 promoter E-box region in the breast cancer cells. Such a switch in transcriptional activators would be expected to interfere with the regulation of the promoter. In agreement with this hypothesis, we found that the nature of the modifications present on the CDK4 promoter-associated histones was different in MCF-7 and MDA-MB-231 as compared to MCF-10A cells. As shown in Figure 8b , there was markedly more acetylated histone H3 at the CDK4 promoter in MCF-10A cells than in the breast cancer cells. In contrast, the level of acetylated histone H4 was similar in the three cell lines. These observations indicate a profound alteration in CDK4 transcriptional control in breast cancer cells, with likely alterations in the response of this promoter to various signals. Given the key role of CDK4 in cellular transformation, deregulated CDK4 transcription may be a very significant event in breast carcinogenesis.
Discussion
CDK4 is an essential component of a major growth control pathway that is commonly affected in cancer. Therefore, understanding how CDK4 expression is modulated at the transcriptional level can reveal novel mechanisms for its deregulation in cancer cells. In the present study, two different transcription factor families, c-Myc and USF, with opposite activities in cellular transformation assays, were found to cooperate in activating CDK4 transcription in non-tumorigenic breast epithelial cells. In contrast, CDK4 expression was independent of both c-Myc and USF in two Figure 7 Transcription factor occupancy at the endogenous CDK4 promoter in normal versus breast cancer cell lines. Equivalent amounts of crosslinked chromatin from MCF10A, MCF-7, and MDA-MB-231 cells were immunoprecipitated with antibodies to USF1 or USF2 (a) and c-Myc (b). The crosslinks were then reversed, and the immunoprecipitated DNA was purified for quantitation by real-time PCR. Primer sets were designed to amplify the chromosomal DNA regions of the CDK4 promoter and CDK4 exon 8 as negative control Several pieces of evidence demonstrate joint control of CDK4 transcription by USF and c-Myc in MCF-10A cells. First, E-box-dependent promoter activity in transient transfection assay was enhanced by overexpression of either USF2 or c-Myc, and was repressed by cotransfection of corresponding dominant-negative mutants (Figure 3) . Second, ChIP analysis revealed both USF and c-Myc bound to the CDK4 promoter in vivo (Figure 7) . Third, endogenous CDK4 expression was strongly inhibited by overexpression of USF-specific as well as Myc-specific dominant-negative mutants ( Figure 5 ). Together, these experiments establish CDK4 as a direct target of both USF and c-Myc in breast epithelial cells, with each transcription factor contributing strongly to promoter activation. Since the CDK4 promoter contains multiple E boxes, it is possible that USF and c-Myc bind simultaneously to adjacent sites and act cooperatively to activate transcription. Alternatively, different promoters in a given cell population may bind exclusively USF dimers or cMyc-Max dimers, with the distribution possibly changing with the cell cycle. Several observations would argue in favor of the idea that USF and c-Myc bind in tandem. For example, cotransfection of both A-USF and A-Max did not inhibit CDK4 transcription more than transfection of either dominant-negative mutant alone. Also, excess USF2 in the presence of A-Max, or excess c-Myc in the presence of A-USF did not restore promoter activity to the level due to endogenous transcription factors, which would be expected if USF and c-Myc acted on different populations of promoters (data not shown). Finally, the drastically decreased level of CDK4-bound Myc in the breast cancer cells, coincident with loss of USF function, also points to cooperation or co-stabilization of the two transcription factors at the CDK4 promoter in normal cells.
Understanding E-box-mediated gene regulation in higher eucaryotes is complicated by the redundancy of transcription factors that can interact with the same motifs. For example, E boxes containing a CACGTG core sequence can be recognized not only by USF and Myc but also by various members of the TFE3/TFEB/ MiTF (Beckmann et al., 1990; Fisher et al., 1991; Yasumoto et al., 1994) , sterol regulatory elementbinding protein (SREBP; Athanikar and Osborne, 1998), and ARNT/HIF (Swanson and Yang, 1999) families. In addition, different members of each of these families can exert opposite effects on gene transcription. Our studies have provided strong evidence for c-Myc and USF2 involvement in CDK4 activation in nontumorigenic breast epithelial cells. The exact role played by USF1, however, remains unclear. Endogenous USF1 is clearly bound to the CDK4 promoter in vivo, most probably as a heterodimer with USF2 ( Figure 7 ). Yet, exogenous USF1 did not activate the CDK4 promoter in transient transfection assay, while USF2 did (Figure 3) . Similar results were previously reported for the IGF2R promoter in MCF-10A cells (Szentirmay et al., 2003) . It may be that USF2-interacting cofactors are more abundant than USF1-interacting cofactors in mammary epithelial cells, and that opposite results will be obtained in other cell types. Alternatively, the specificity may reflect the presence of different activation domains in USF1 and USF2.
CDK4 being a downstream target of USF in general, and USF2 in particular, may account for aspects of the phenotype of the USF-deficient mice. Knockout mice lacking USF1 are essentially normal, but have higher amounts of USF2, which probably compensates for the loss of USF1. In contrast, USF2-null mice have less USF1 than their w.t. littermates, and thus considerably lower overall USF levels. USF2-null mice display dwarfism and decreased fertility (Sirito et al., 1998; Hadsell et al., 2003) , two phenotypic traits also observed in the CDK4À/À mice (Rane et al., 1999; Tsutsui et al., 1999) .
In our analysis, expression of the A-Mitf dominantnegative mutant, which should have prevented DNA binding by TFE3-related proteins (Krylov et al., 1997) , had little effect on CDK4 expression in normal or breast cancer cell lines (data not shown). This result would exclude a major involvement of the TFE3 family in these cells. However, the situation could be different in other cell types. It is noteworthy that the relative importance of the various CDK4 promoter E boxes was different in RAT1 cells (Hermeking et al., 2000) as compared to MCF-10A cells (Figure 2) , perhaps reflecting a different composition of the transcription complexes in these two cell types. Possible regulation of CDK4 by other Myc family members besides c-Myc also needs to be considered. A recent study using cells from mice lacking the Mnt gene revealed that Mnt, a Myc-related, ubiquitously expressed transcriptional repressor, bound to and inhibited the CDK4 promoter in embryonic fibroblasts, while simultaneously downregulating c-Myc expression (Hurlin et al., 2003) .
Overexpression of c-Myc is common in cancer cells. Accordingly, there is four-to sixfold more c-Myc in MDA-MB-231 and MCF-7 cells than in MCF-10A cells ). Yet, analysis by ChIP revealed a 10-fold decrease in the amount of c-Myc bound to the CDK4 promoter in the two cancer cell lines as compared to MCF-10A (Figure 7) . The nature of the relationship between the concomitant loss of USF and c-Myc transcriptional activities at the CDK4 promoter remains to be demonstrated. However, our results raise the possibility that the two transcription factors must act in concert to activate CDK4 and that the CDK4 promoter binds a transcription factor complex that contains both USF and c-Myc. The loss of USF function in cancer cells has been attributed to the absence or inactivation of unidentified USF-specific cofactors Qyang et al., 1999) . Absence of these cofactors may destabilize the USF/c-Myc transcription factor complex on the CDK4 promoter, thereby permitting other transcription factors to bind the CDK4 E-box region.
Existence of a major switch in the nature of the transcription factors bound to the CDK4 promoter in normal versus breast cancer cells was further demonstrated by the altered pattern of acetylated histones in the associated chromatin (Figure 8) . Modifications of the tails of core histones, which decreases chromatin condensation, is an important mechanism controlling transcription in eucaryotes, and different histone-modifying enzymes are recruited to promoters by different transcription factors. Our experiments revealed significantly higher levels of histone H3 acetylation near the CDK4 promoter in MCF-10A than in MCF-7 and MDA-MB-231 cells, while the levels of acetylated histone H4 were similar in the three cell lines. This difference in histone H3 acetylation may reflect the activity of USF, or lack thereof, since similar results were obtained for the IGF2R promoter, which does not bind c-Myc in these cell lines (unpublished observation). USF binding may direct the preferential association of particular chromatin-modifying enzymes. Consistent with this idea, Weissman et al. (2000) showed that, in baby hamster kidney cells, USF-dependent promoters specifically recruit TAF II 250, an acetyltransferase with a preference for histone H3 as a substrate (Mizzen et al., 1996) .
Prior evidence linking the biological activities of USF and c-Myc came from in vitro cellular transformation assays in which USF overexpression can specifically antagonize the oncogenic activity of c-Myc (Luo and Sawadogo, 1996a) . The mechanisms of this functional antagonism are unknown, but likely involve some of the specific downstream targets of the two transcription factors, since there is no evidence that USF and c-Myc physically interact. The surprising finding that USF and c-Myc jointly activate CDK4 demonstrates that the relationship between the biological functions of USF and c-Myc is more complex than previously suspected. Significantly, cooperation between USF and c-Myc at the CDK4 promoter does not occur in cancer cells, and our results point to a major switch in the transcription factors controlling CDK4 expression during breast carcinogenesis. Whatever the nature of the transcription factors that substitute for USF and c-Myc is, this switch has critical importance for the regulation of the CDK4 gene and its ability to respond to various signals in cancer cells.
Materials and methods
Plasmids
PCR primers, 5
0 -CAGCATCACCTCTGGTACCCC-3 0 and 5 0 -CCAAGCTTGGGCGG-GGCGAACGCCGAC-3 0 , were used to amplify the À439 to þ 4 region of the CDK4 promoter (GenBank no. AF224272) from HeLa genomic DNA. The PCR product was subcloned into the KpnI/HindIII sites of the pGL3luc basic vector to generate pCDK4-Luc. The CDK4 promoter constructs with mutated E boxes were as described in Hermeking et al. (2000) . The pSG5-derived USF expression plasmids (Luo and Sawadogo, 1996a, b) , the c-Myc expression plasmid (Land et al., 1986) , and the HA-tagged A-USF and AMax dominant-negative mutants (Krylov et al., 1997; Qyang et al, 1999) were all previously described.
DNase I footprinting
The PCR primers, 5 0 -GTGGCCTAGGTTGCCATGGCAC-3 0 and 5 0 -GCTGTC-CAGCGGTTCCATCTTC-3 0 , were used to amplify from pCDK4-Luc a 347-bp DNA fragment comprising the four E boxes of the CDK4 promoter. Uniquely labeled DNA fragments, obtained by PCR amplification using one 5 0 -end-labeled primer and one unlabeled primer, were purified from agarose gels using NA45 DEAE-cellulose membranes (Schleicher & Schuell). Footprinting reactions (25 ml) containing the labeled probe (10 000 cpm) and increasing amounts (0-10 ng) of rUSF1 (Van Dyke et al., 1992) were incubated at 301C for 30 min, followed by treatment with DNase I (140 ng) for 30 s. The reactions were stopped and processed as described (Sawadogo and Roeder, 1985) . Size markers were generated by G-specific chemical sequencing of the probe (Maxam and Gilbert, 1977) .
Cell culture and transient transfections
MCF-10A, MCF-7, and MDA-MB-231 cells were propagated as previously described . For transient transfection experiments, cells were seeded in six-well plates at typically 3 Â 10 5 cells per well and transfected 18À20 h later using 6 ml of Fugene 6 reagent (Roche Biochemicals) and 1 mg of reporter plasmid and 1 mg of USF or c-Myc expression vector (or the corresponding empty vector) or 0.1 mg of A-Max or A-USF. In each case, 50 ng of pRL-SV40 (Promega) was added as internal control. After 44-48 h, the cells were washed twice with phosphate-buffered saline (PBS) before harvesting with 100 ml of lysis buffer (25 mM Tris-HCl pH 7.9, 1% Triton X-100, 2 mM EDTA, 10% glycerol, 2 mM dithiothreitol) for 15 min at room temperature. The lysates were centrifuged briefly at 10 000 rpm and 10 ml of the supernatant was assayed for luciferase using a Monolight 2010 luminometer apparatus using either the previously described assay buffer (Luo and Sawadogo, 1996b) or the Dual-Luciferase Reporter Assay system (Promega). Data points are the averaged results of three or more independent transfections. Error bars represent one standard deviation.
Western blots
Proteins from 10 ml of whole-cell luciferase lysates or FACSseparated transfected cells (20 000 cells per lane) or whole-cell lysates (40 000 cells per lane) were resolved on 12% SDS-polyacrylamide gels and electroblotted to nitrocellulose. Blots were probed with antibodies to USF1 (C-20, sc-229, Santa Cruz Biotechnology), USF2 (N-18, sc-861 and C-20, sc-862, Santa Cruz Biotechnology), c-Myc (N-262, sc-764, Santa Cruz Biotechnology), CDK4 (C-22, DB011, Delta Biolabs), or b-actin (AC-15, Sigma). HA-tagged A-USF and A-Max proteins were detected using a mouse monoclonal antibody (12 CA5, Roche). The blots were developed using peroxidaseconjugated anti-rabbit or anti-mouse secondary IgGs and visualized by ECL (Pierce). Quantitation of the immunoblots was performed using the ImageJ software.
ChIP
Cells in monolayer were crosslinked by addition of 1% formaldehyde as described (Boyd and Farnham, 1999; Szentirmay et al., 2003) . Antibodies to USF1, USF2 (N-18), cMyc, Ac-Histone H3 (06-599, Upstate Biotechnology) or AcHistone H4 (06-598, Upstate Biotechnology) were added to the pre-cleared chromatin extract and incubated overnight at 41C with gentle rotation. A mock reaction with no added antibodies was carried out in parallel. The pellets resulting from incubation of the extract with Staphylococcus aureus cells were washed extensively before incubation with the elution buffer (Boyd and Farnham, 1999) . The supernatant of the mock reaction served as the input sample and was processed in parallel with the immunoprecipitates when reversing the crosslinks by heating at 651C for 5 h. After digestion with proteinase K, the DNA was analysed by PCR with the following primers: CDK4 promoter (GenBank no. AF224272), 5 0 -GTGGCCTAGGTTGCCATGGCAC-3 0 (F) and 5 0 -CTCA CCATGTGACCAGCTGCC-3 0 (R), product size 347 bp; CDK4 exon 8 (GenBank no. AY034380), 5 0 -GACACTGAG AGGGCAATCTTTG-3 0 (F) and 5 0 -GGAAAGGGACAAGA GGGAAC-3 0 (R), product size 187 bp. For quantitative PCR, serial dilutions of the input sample served as standards to make a calibration curve. The concentration of the immunoprecipitated DNA was calculated by the LightCycler software (Roche) and plotted as percentage of total genomic DNA input.
Separation of transfected cells and RT-PCR
In all, 2 Â 10 6 MCF-10A cells were seeded in a 75 cm 2 flask and transfected 20 h later with 2 mg of the expression plasmids for A-USF, A-Max or control vector pRc566 and 10 mg of pEGFP-F (Clontech) using 60 ml of Fugene 6 reagent (Roche) and 940 ml of serum-free medium. After 48 h, the cells were detached by trypsin-EDTA, washed, resuspended in PBS and sorted by a BD FACS Vantage SE flow cytometer (San Jose, CA, USA) based on the GFP fluorescence. Mock-transfected cells were used to set the background fluorescence threshold. Total RNA was isolated from the sorted cells using Tripure reagent (Roche). cDNA was prepared from 2 mg of each RNA sample using Superscript II Reverse Transcriptase (Invitrogen) according to the manufacturer's instructions. A 1-2 ml aliquot of cDNA was used to quantitate the CDK4 and ELF1a transcripts by real-time PCR using the following primers: CDK4, 5 0 -TCTGGTACCGAGCTCCCGAA-3 0 (F) and 5 0 -GA TTTGCCCAACTGGTCGG-3 0 (R) (GenBank no. U37022), 146-bp product; and ELF1a, 5 0 -CACACGGCTCACATTG CAT-3 0 (F) and 5 0 -CACGAACAGCAAAGCGACC-3 0 (R) (GenBank no. AYO43301), 288-bp product.
